{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:21Z","timestamp":1777602801528,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dmd.2025.100107","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:13:27Z","timestamp":1748949207000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase"],"prefix":"10.1016","volume":"53","author":[{"given":"Nicola","family":"Colclough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra L.","family":"Orton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-4371","authenticated-orcid":false,"given":"Venkatesh Pilla","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshini","family":"Markandu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-8498","authenticated-orcid":false,"given":"Jennie","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-2920","authenticated-orcid":false,"given":"Aixiang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petar","family":"Pop-Damkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-8862","authenticated-orcid":false,"given":"Thomas A.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-7500","authenticated-orcid":false,"given":"Kurt G.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot F.","family":"McGinnity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib1","first-page":"121","article-title":"Current trends in the surgical management and treatment of adult glioblastoma","volume":"3","author":"Young","year":"2015","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.dmd.2025.100107_bib2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: a review on the impact of treatment modalities","volume":"18","author":"Delgado-L\u00f3pez","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molonc.2011.05.001","article-title":"Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?","volume":"5","author":"Mannino","year":"2011","journal-title":"Mol Oncol"},{"issue":"6922","key":"10.1016\/j.dmd.2025.100107_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Mol Oncol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib7","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"Pike","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.dmd.2025.100107_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/dmd.114.061804","article-title":"A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834","volume":"43","author":"Sodhi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100107_bib9","series-title":"Enzyme Systems that Metabolise Drugs and Other Xenobiotics","first-page":"147","article-title":"Molybdenum hydroxylases","author":"Beedham","year":"2001"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.120.000313","article-title":"Contribution of extrahepatic aldehyde oxidase activity to human clearance","volume":"49","author":"Kozminski","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100107_bib11","first-page":"745","article-title":"Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining","volume":"16","author":"Moriwaki","year":"2001","journal-title":"Histol Histopathol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100107_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/187231208785425818","article-title":"Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human","volume":"2","author":"Sahi","year":"2008","journal-title":"Drug Metab Lett"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib13","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1124\/dmd.123.001379","article-title":"Dissecting parameters contributing to the underprediction of aldehyde oxidase-mediated metabolic clearance of drugs","volume":"51","author":"Subash","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100107_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1124\/dmd.123.001436","article-title":"Challenges and opportunities for in vitro\u2013in vivo extrapolation of aldehyde oxidase-mediated clearance: toward a roadmap for quantitative translation","volume":"51","author":"Izat","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100107_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3109\/00498258409151492","article-title":"A species difference in the presystemic metabolism of carbazeran in dog and man","volume":"14","author":"Kaye","year":"1984","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2025.100107_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/00498258509045354","article-title":"Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man","volume":"15","author":"Kaye","year":"1985","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1124\/dmd.109.030783","article-title":"Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences","volume":"38","author":"Dalvie","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib18","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-14-3258","article-title":"The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation","volume":"21","author":"Lolkema","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/dmd.116.072793","article-title":"Lack of exposure in a first-in-man study due to aldehyde oxidase metabolism: investigated by use of 14C-microdose, humanized mice, monkey pharmacokinetics, and in vitro methods","volume":"45","author":"Jensen","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100107_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/00498254.2010.549970","article-title":"Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans","volume":"41","author":"Akabane","year":"2011","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.dmd.2025.100107_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0959-8049(02)00020-5","article-title":"Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration","volume":"38","author":"Dittrich","year":"2002","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.dmd.2025.100107_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib23","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1021\/acs.jmedchem.3c02277","article-title":"Identification of novel, selective ataxia-telangiectasia mutated kinase inhibitors with the ability to penetrate the blood-brain barrier: the discovery of AZD1390","volume":"67","author":"Pike","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2025.100107_bib24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2019.01.015","article-title":"Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery","volume":"24","author":"Colclough","year":"2019","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.dmd.2025.100107_bib25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1021\/acs.molpharmaceut.2c00014","article-title":"Identification and strategies to mitigate high total clearance of benzylamine-substituted biphenyl ring systems","volume":"19","author":"Williamson","year":"2022","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib26","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1002\/jps.22550","article-title":"PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach","volume":"100","author":"Poulin","year":"2011","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100107_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-6670(17)44557-5","article-title":"A Multi-compartmental model generally applicable to physiologically-based pharmacokinetics","volume":"30","author":"Arundel","year":"1997","journal-title":"IFAC Proc Vol"},{"issue":"26","key":"10.1016\/j.dmd.2025.100107_bib28","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/S0024-3205(98)00525-6","article-title":"Interspecies scaling of renally secreted drugs","volume":"63","author":"Mahmood","year":"1998","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.dmd.2025.100107_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.110.037267","article-title":"Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption","volume":"39","author":"Paine","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00498254.2012.669080","article-title":"Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes","volume":"42","author":"Sohlenius-Sternbeck","year":"2012","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib31","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.105.004259","article-title":"A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes","volume":"33","author":"Riley","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100107_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/138920007780866799","article-title":"Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs","volume":"8","author":"McGinnity","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jps.2600680948","article-title":"Effect of altered plasma protein binding on apparent volume of distribution","volume":"68","author":"Oie","year":"1979","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0091270003260336","article-title":"Human liver aldehyde oxidase: inhibition by 239 drugs","volume":"44","author":"Obach","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/mTOR dual inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11095-004-9015-1","article-title":"Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches","volume":"22","author":"Ito","year":"2005","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100107_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/dmd.123.001476","article-title":"Utilizing a dual human transporter MDCKII-MDR1-BCRP cell line to assess efflux at the blood brain barrier","volume":"52","author":"Colclough","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100107_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/00498254.2015.1096981","article-title":"Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase","volume":"46","author":"Isobe","year":"2016","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/tpj.2010.8","article-title":"In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor","volume":"11","author":"Zhang","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"23","key":"10.1016\/j.dmd.2025.100107_bib41","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1021\/jm900729s","article-title":"Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections","volume":"52","author":"Magee","year":"2009","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.dmd.2025.100107_bib42","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.bmcl.2012.02.069","article-title":"Medicinal chemistry approaches to avoid aldehyde oxidase metabolism","volume":"22","author":"Pryde","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"10.1016\/j.dmd.2025.100107_bib43","doi-asserted-by":"crossref","first-page":"10955","DOI":"10.1021\/acs.jmedchem.9b00875","article-title":"Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery","volume":"62","author":"Manevski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmd.2025.100107_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2019.05.011","article-title":"Aldehyde oxidase and its role as a drug metabolizing enzyme","volume":"201","author":"Dalvie","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2025.100107_bib45","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/dmd.124.001802","article-title":"The drug-drug interaction between erlotinib and OSI-930 is mediated through aldehyde oxidase inhibition","volume":"52","author":"Tang","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/00498250210158221","article-title":"Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices","volume":"32","author":"Renwick","year":"2002","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2025.100107_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.32.1.89","article-title":"Potent inhibition of human liver aldehyde oxidase by raloxifene","volume":"32","author":"Obach","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100107_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/17425255.2013.738668","article-title":"Strategies for a comprehensive understanding of metabolism by aldehyde oxidase","volume":"9","author":"Hutzler","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100107_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/00498254.2017.1296208","article-title":"A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry","volume":"48","author":"Crouch","year":"2018","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/17425255.2012.663352","article-title":"The role of aldehyde oxidase in drug metabolism","volume":"8","author":"Garattini","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03189919","article-title":"Species variation in hepatic aldehyde oxidase activity","volume":"12","author":"Beedham","year":"1987","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2025.100107_bib52","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1124\/dmd.113.052985","article-title":"Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase","volume":"41","author":"Choughule","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100107_bib53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans\u2014a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"issue":"suppl 2","key":"10.1016\/j.dmd.2025.100107_bib54","article-title":"505MO A phase 0\/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients [Abstract]","volume":"34","author":"Sanai","year":"2023","journal-title":"Ann Oncol"},{"issue":"2 suppl","key":"10.1016\/j.dmd.2025.100107_bib55","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","article-title":"Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma [Abstract]","volume":"120","author":"Yang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:13:17Z","timestamp":1756289597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0090955625091160"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100107","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}